Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07855991) titled 'A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment' on Sept. 29.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).
Primary Sponsor: BeOne Medicines
Condition:
Hepatic Impairment
Healthy Adult Participants
Intervention:
Drug: Sonrotoclax
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 15, 2026
Target Sample Size: 12
To know more, visit https://clinicaltrials.gov/study/NCT07855991...